NO20076063L - Prodroger av N-tiazol-2-yl-benzamidderivater - Google Patents

Prodroger av N-tiazol-2-yl-benzamidderivater

Info

Publication number
NO20076063L
NO20076063L NO20076063A NO20076063A NO20076063L NO 20076063 L NO20076063 L NO 20076063L NO 20076063 A NO20076063 A NO 20076063A NO 20076063 A NO20076063 A NO 20076063A NO 20076063 L NO20076063 L NO 20076063L
Authority
NO
Norway
Prior art keywords
prodrugs
thiazol
benzamide derivatives
compounds
receptor
Prior art date
Application number
NO20076063A
Other languages
English (en)
Inventor
Gitte Mikkelsen
Benny Bang-Andersen
Mogens Larsen
Anette Graven Sams
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20076063L publication Critical patent/NO20076063L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen vedrører forbindelser med formel I, hvori variablene er som definert i kravene. Forbindelsene er prodroger av A2A-reseptorligander med forbedret vandig løselighet, og er nyttige i behandlingen av nevrologiske og psykiatriske forstyrrelser, hvor en A2A-reseptor er omfattet.
NO20076063A 2005-04-25 2007-11-26 Prodroger av N-tiazol-2-yl-benzamidderivater NO20076063L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200500594 2005-04-25
DKPA200501331 2005-09-26
DKPA200600445 2006-03-28
PCT/DK2006/000212 WO2006114093A1 (en) 2005-04-25 2006-04-24 Pro-drugs of n-thiazol-2yl-benzamide derivatives

Publications (1)

Publication Number Publication Date
NO20076063L true NO20076063L (no) 2007-11-26

Family

ID=36617296

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076063A NO20076063L (no) 2005-04-25 2007-11-26 Prodroger av N-tiazol-2-yl-benzamidderivater

Country Status (13)

Country Link
EP (1) EP1877391A1 (no)
JP (1) JP2008538772A (no)
KR (1) KR20080000607A (no)
AR (1) AR054032A1 (no)
AU (1) AU2006239642A1 (no)
BR (1) BRPI0609565A2 (no)
CA (1) CA2606011A1 (no)
EA (1) EA200702332A1 (no)
IL (1) IL186143A0 (no)
MX (1) MX2007012552A (no)
NO (1) NO20076063L (no)
TW (1) TW200720264A (no)
WO (1) WO2006114093A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010140339A1 (ja) * 2009-06-01 2010-12-09 武田薬品工業株式会社 複素環化合物
EP2655377B1 (en) * 2010-12-20 2016-03-30 Glenmark Pharmaceuticals S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
TW200524887A (en) * 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
US20080312435A1 (en) * 2004-11-15 2008-12-18 Taisho Pharmaceutical Co., Ltd. Imine Compound

Also Published As

Publication number Publication date
CA2606011A1 (en) 2006-11-02
EP1877391A1 (en) 2008-01-16
IL186143A0 (en) 2008-01-20
AU2006239642A1 (en) 2006-11-02
JP2008538772A (ja) 2008-11-06
AR054032A1 (es) 2007-05-30
BRPI0609565A2 (pt) 2011-10-18
KR20080000607A (ko) 2008-01-02
EA200702332A1 (ru) 2008-04-28
MX2007012552A (es) 2007-11-16
WO2006114093A1 (en) 2006-11-02
TW200720264A (en) 2007-06-01

Similar Documents

Publication Publication Date Title
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
NO20076371L (no) Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
TW200722079A (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
ATE530519T1 (de) Cyclobutylaminderivate
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
WO2006021379A8 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
EP1740581A4 (en) PYRIDYL DERIVATIVE COMPOUNDS SUBSTITUTED AT POSITIONS 2, 4, 6 USEFUL AS INHIBITORS OF BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER'S DISEASE
WO2006021378A8 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
NO20082096L (no) Azaindol-2-karboksamidderivativer
GB0415746D0 (en) Organic compounds
WO2009046842A3 (de) Thialzolderivate zur behandlung von krebs
NO20062417L (no) N-tiazol-2-yl-benzamidderivater
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
MA28635B1 (fr) Methode de production de derives de 1, 4-diphenylazetidinone
EP1817311A4 (en) 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS AS BETA SEKTRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
TW200634013A (en) Quinoline derivative, its use, production and pharmaceutical agents containing the derivative
GB0513886D0 (en) Novel compounds
ZA200709094B (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
ZA200709090B (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
NO20072060L (no) 2-acylaminotiazolderivater
ZA200709096B (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application